HC Wainwright Issues Optimistic Estimate for KYMR Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at HC Wainwright upped their Q2 2025 EPS estimates for Kymera Therapeutics in a research report issued on Monday, May 12th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.77) per share for the quarter, up from their previous forecast of ($0.78). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics’ FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($3.35) EPS, FY2027 earnings at ($3.71) EPS, FY2028 earnings at ($2.59) EPS and FY2029 earnings at ($0.72) EPS.

KYMR has been the topic of several other reports. Stephens reaffirmed an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Guggenheim reaffirmed a “buy” rating and set a $52.00 price objective on shares of Kymera Therapeutics in a report on Monday, May 12th. Bank of America decreased their price target on Kymera Therapeutics from $47.00 to $44.00 and set a “neutral” rating on the stock in a research report on Monday, May 12th. Citigroup initiated coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $52.00 price target on the stock. Finally, UBS Group decreased their price target on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $55.27.

Kymera Therapeutics Stock Up 0.8%

NASDAQ KYMR opened at $30.25 on Thursday. The company has a market cap of $1.97 billion, a PE ratio of -12.93 and a beta of 2.18. Kymera Therapeutics has a 52 week low of $19.45 and a 52 week high of $53.27. The firm’s 50-day simple moving average is $29.36 and its two-hundred day simple moving average is $37.05.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company’s revenue was up 114.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.69) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its position in shares of Kymera Therapeutics by 3.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company’s stock worth $276,395,000 after purchasing an additional 224,859 shares during the last quarter. Wellington Management Group LLP boosted its stake in Kymera Therapeutics by 13.0% in the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock worth $164,134,000 after buying an additional 689,547 shares in the last quarter. Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 7.0% in the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after buying an additional 344,080 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Kymera Therapeutics by 14.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock worth $207,184,000 after buying an additional 650,000 shares in the last quarter. Finally, Siren L.L.C. boosted its stake in Kymera Therapeutics by 9.1% in the first quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock worth $88,687,000 after buying an additional 270,580 shares in the last quarter.

Insider Buying and Selling

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. This represents a 2.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. This trade represents a 2.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,659 shares of company stock worth $324,567. Insiders own 16.01% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.